Author: Jesse Landry

Most people think precision is a feature. At PreciseDx, it’s the point. And with $11 million in fresh Series B-II capital lighting the path forward, they’re making it abundantly clear: in the business of cancer diagnostics, close enough is never good enough. Born out of Mount Sinai’s deep bench of computational pathology, PreciseDx didn’t stumble into AI-driven digital diagnostics, they were engineering it before most med-tech startups figured out the difference between a slide and a scanner. What started as a spin-out in 2020 is now a full-force movement, armed with clinical validation across more than 3,000 breast cancer cases…

In 2004, a Duke football lineman walked into a classroom with more bruises than free time and built a digital calendar so his coaches would stop scheduling lifts like sadistic game shows. That student-athlete was Zach Maurides, and what started as a calendar turned into Teamworks, the Operating System for Sports™, a platform now trusted by every NFL team, most major league franchises, and more Olympic federations than the IOC could alphabetize. Fast forward to June 17, 2025. Teamworks just locked in a $235 million Series F, led once again by Dragoneer Investment Group, pushing its pre-money valuation north of…

There’s a reason orthopedic care still feels like a bad remix of 1997 healthcare. Everyone’s still paging each other like it’s ER, triaging by guesswork, and drowning in follow-up calls that should’ve been AI’d three years ago. Enter RevelAi Health, the company making sure musculoskeletal care doesn’t limp into the future. Just locked in a $3.1M oversubscribed seed round, RevelAi Health is putting conversational AI to work where it’s desperately needed, the $420B musculoskeletal market that’s been living rent-free in the healthcare system’s blind spot. And this isn’t your average health tech fluff. We’re talking enterprise-grade, SOC2 Type2 certified, multilingual,…

In the world of enterprise AI, there’s talk, and then there’s Maven AGI. One year ago, they weren’t even on the map. Today, they’re turning that map into kindling. Because when a startup rolls out from the minds of Jonathan Corbin (ex-HubSpot), Sami Shalabi (ex-Google, 55+ patents deep), and Eugene Mann (ex-Stripe, machine learning whisperer), you don’t get a company. You get a signal. And this week, that signal just got a whole lot louder: $50 million in Series B from Dell Technologies Capital, with Cisco Investments and SE Ventures joining the party, alongside returning believers like Lux Capital, M13,…

Call it modern magic: a PCR test that fits in the palm of your hand and delivers lab-grade results faster than your coffee order at Blue Bottle. Especially when it comes from a company called Visby Medical, a name that sounds like it belongs on a spaceship but is busy transforming your living room into a diagnostic command center. While Big Healthcare is still out here playing dial-up, Adam de la Zerda and team are dropping fiber-optic level speed with real-world stakes: STIs, COVID, flu. And now, a first-of-its-kind FDA-approved over-the-counter women’s sexual health PCR test, straight from box to…

Let’s talk about control, not the illusion, the real kind. The kind that lets an enterprise know exactly what’s running on 100,000+ devices scattered across continents, clouds, coffee shops, and chaos. Most companies? They’re flying blind. Fleet? They see everything. And they just landed $27 million in fresh Series B fuel to double down on their open-source device management platform that already secures more than 1.65 million devices worldwide. Led by Ten Eleven Ventures, with returning conviction from CRV, plus bets from Open Core Ventures, Moonfire Ventures, and a who’s-who of operator angels, GitLab’s Sid Sijbrandij, Vercel’s Guillermo Rauch, Material…

Some startups build tech. Others build hype. But HydroBlok? They build trust, layer by layer, board by board, using a product that doesn’t just hold water, it owns it. Born in Draper, Utah and now making noise across North America, HydroBlok just locked in $6 million in Series A extension funding to scale up what the construction industry has quietly known for a decade: these guys aren’t here to follow trends, they’re here to seal the future. Led by Pier 88 Investment Partners and Andina Capital Partners, this isn’t some speculative play, it’s a bet on fundamentals, patents, and performance.…

If you’ve ever tried to explain wire fraud to your parents, you already know: elder financial safety isn’t a niche issue, it’s a five-alarm fire dressed in a cable-knit sweater. And while most fintechs are still trying to gamify checking accounts, Carefull has been quietly building the AI-powered fireproof vault for aging adults and the 45 million Americans who care for them. Now, with a fresh injection of growth capital from CIBC Innovation Banking, the company’s not just expanding, it’s fortifying the front lines of financial protection for the generation holding 83% of U.S. household wealth. Todd Rovak and Max…

You know that feeling when a biotech startup raises $66M, and it doesn’t just feel like a funding round, it feels like a fireworks mortar shot into the sky over San Diego? That’s Actio Biosciences, clinical-stage, precision-driven, and moving with the kind of clarity that only comes from translating the deepest layers of human genetics into something the rest of us can actually use, medicine. Founded in 2021 by David Goldstein, Ph.D. and John McHutchison, M.D., Actio wasn’t built on vibes, it was built on decades of data, discovery, and the kind of experience that doesn’t need a hype man.…

There’s something about a biotech born from a Starbucks meetup and a Johns Hopkins lab, then going on to decode the immune system like it’s reading sheet music. Baltimore’s Infinity Bio just locked in an $8M Series A, led by Illumina Ventures, backed by PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. And while headlines love a dollar amount, this one’s about capacity, specifically, the capacity to make sense of immune chaos at scale. In just two years, Dr. H. Benjamin Larman took his academic research and built a platform that speaks fluent immune response. Joy Nassif brought the operational…